1. Py-CoMFA, docking, and molecular dynamics simulations of Leishmania (L.) amazonensis arginase inhibitors.
- Author
-
Camargo PG, Dos Santos CR, Girão Albuquerque M, Rangel Rodrigues C, and Lima CHDS
- Subjects
- Quantitative Structure-Activity Relationship, Protozoan Proteins antagonists & inhibitors, Protozoan Proteins chemistry, Protozoan Proteins metabolism, Allosteric Site, Antiprotozoal Agents pharmacology, Antiprotozoal Agents chemistry, Catalytic Domain, Arginase antagonists & inhibitors, Arginase chemistry, Arginase metabolism, Molecular Dynamics Simulation, Molecular Docking Simulation, Leishmania enzymology, Leishmania drug effects, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology
- Abstract
Leishmaniasis is a disease caused by a protozoan of the genus Leishmania, affecting millions of people, mainly in tropical countries, due to poor social conditions and low economic development. First-line chemotherapeutic agents involve highly toxic pentavalent antimonials, while treatment failure is mainly due to the emergence of drug-resistant strains. Leishmania arginase (ARG) enzyme is vital in pathogenicity and contributes to a higher infection rate, thus representing a potential drug target. This study helps in designing ARG inhibitors for the treatment of leishmaniasis. Py-CoMFA (3D-QSAR) models were constructed using 34 inhibitors from different chemical classes against ARG from L. (L.) amazonensis (LaARG). The 3D-QSAR predictions showed an excellent correlation between experimental and calculated pIC
50 values. The molecular docking study identified the favorable hydrophobicity contribution of phenyl and cyclohexyl groups as substituents in the enzyme allosteric site. Molecular dynamics simulations of selected protein-ligand complexes were conducted to understand derivatives' interaction modes and affinity in both active and allosteric sites. Two cinnamide compounds, 7g and 7k, were identified, with similar structures to the reference 4h allosteric site inhibitor. These compounds can guide the development of more effective arginase inhibitors as potential antileishmanial drugs., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF